Ozempic in Adults 65 and Older: Off-Label Uses, Dosing Adjustments, and Safety Considerations

What the FDA Actually Approves for Older Adults

Ozempic carries no upper age restriction in its label. The FDA approval covers glycemic control in type 2 diabetes and, following SUSTAIN-6 data, reduction of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease [1]. Age-stratified subgroup analyses from SUSTAIN-6 showed that patients 65 and older represented roughly 33% of the trial population, and their MACE reduction was consistent with the overall 26% relative risk reduction (hazard ratio 0.74, 95% CI 0.58 to 0.95) [1].

What the Label Says About Geriatric Use

The Ozempic prescribing information states: "No dose adjustment is recommended based on age" [2]. That sentence is technically accurate for pharmacokinetics. Semaglutide clearance does not change meaningfully with age in population pharmacokinetic modeling [2]. The label does not, however, account for the syndromic complexity common in older patients: polypharmacy, sarcopenia, reduced thirst perception, and baseline frailty.

Why Age-Neutral Dosing Can Still Be Dangerous

Starting at 0.25 mg weekly and titrating every 4 weeks remains the standard approach across all adult age groups. A 78-year-old with a body mass index of 23 kg/m² and moderate chronic kidney disease is pharmacokinetically equivalent to a 45-year-old. Clinically, they are not. The 2024 ADA Standards of Care explicitly recommend individualizing therapy in older adults, prioritizing agents with low hypoglycemia risk and favorable weight profiles, and assessing functional status before titrating GLP-1 receptor agonists [3].

Off-Label Uses in Geriatric Patients

Obesity and Weight Management

Ozempic is not FDA-approved for obesity; that indication belongs to semaglutide 2.4 mg (Wegovy). Off-label use of Ozempic 1.0 to 2.0 mg for weight reduction in older adults is common in clinical practice, driven partly by insurance coverage patterns. In STEP-1 (N=1,961, mean age 46 years), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [4]. Adults 65 and older were underrepresented in STEP-1, but STEP-5 (N=304, 104-week duration) showed 15.2% sustained weight loss at 2 years, with 10% of participants older than 65 [5].

Weight loss in older adults is not unconditionally beneficial. The Minnesota Obesity Society and multiple geriatric medicine societies note that fat-free mass loss accompanying GLP-1-mediated weight reduction may worsen existing sarcopenia [6]. One systematic review (10 trials, N=17,340) found that GLP-1 receptor agonists reduced lean mass by approximately 25 to 39% of total weight lost, a ratio that worsens with age [6].

Possible Neuroprotective and Cognitive Benefits

This is an active and genuinely preliminary area. Several observational studies suggest GLP-1 receptor agonists may reduce the incidence of Parkinson's disease and Alzheimer's disease. A 2023 study in JAMA Neurology (N=89,205 propensity-matched pairs from Danish registries) found that GLP-1 agonist users had a 28% lower rate of incident Parkinson's disease versus non-users over a median follow-up of 7.8 years [7]. The mechanism hypothesized involves neuroinflammation reduction and improved insulin signaling in the central nervous system [7].

The EVOKE trial (NCT04777396), actively enrolling adults aged 60 to 85 with early Alzheimer's disease, is testing oral semaglutide 14 mg daily. Results are expected in 2025 to 2026 and will provide the first randomized data in this space. Until those results are published, prescribing Ozempic specifically for cognitive protection in a 70-year-old is off-label without randomized evidence.

Knee Osteoarthritis and Weight-Related Joint Disease

The STEP-9 trial (N=407) demonstrated that semaglutide 2.4 mg reduced Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores by 41.8 mm on a 100-mm scale versus 27.5 mm with placebo at 68 weeks (P<0.001), in patients with obesity and knee osteoarthritis [8]. The majority of trial participants were older adults, with a mean age of 56 years and a meaningful proportion over 65. Off-label use of Ozempic to reduce joint load in older patients with T2DM and comorbid knee osteoarthritis has some indirect support from these data, though STEP-9 specifically used the higher 2.4 mg dose.

Pharmacokinetics and Dose Adjustments in Older Adults

Semaglutide's half-life of approximately 165 to 184 hours supports once-weekly dosing regardless of age [2]. Renal impairment, common in older adults, does not alter semaglutide exposure significantly because the drug is not renally cleared; it undergoes proteolytic degradation [2]. No dose adjustment is required for estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m², including dialysis patients, per FDA labeling [2].

Practical Titration in Frail Older Adults

Standard titration:

• Weeks 1 to 4: 0.25 mg weekly (not effective for glycemia; tolerability phase only)
• Weeks 5 to 8: 0.5 mg weekly
• Week 9 onward: 1.0 mg weekly if additional glycemic control needed
• Optional escalation to 2.0 mg weekly after at least 4 weeks at 1.0 mg

In a patient 65 or older with baseline weight <70 kg, eGFR <45, or pre-existing nausea from other medications, clinicians may extend each step to 6 to 8 weeks rather than the standard 4. No published randomized data supports an extended titration schedule specifically in geriatric patients, but the approach is consistent with ADA guidance to prioritize tolerability over speed of dose escalation [3].

Managing GI Side Effects in Older Adults

Nausea, vomiting, and diarrhea affect 15 to 44% of patients in the first 8 weeks of semaglutide therapy [2]. In younger adults these side effects are largely self-limiting. In a frail 80-year-old with borderline albumin of 3.2 g/dL, two weeks of reduced oral intake may precipitate acute kidney injury, electrolyte disturbances, or orthostatic hypotension. Proactive counseling on hydration, small meal sizes, and early reporting of persistent vomiting is not optional in this population.

Cardiovascular Benefits in the 65+ Population

SUSTAIN-6 Age Subgroup Data

SUSTAIN-6 (N=3,297, mean age 64.6 years, 83% with established CVD) remains the primary cardiovascular outcomes trial for Ozempic [1]. The primary composite endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 6.6% of semaglutide patients versus 8.9% of placebo patients over 2.1 years. The reduction was driven mainly by nonfatal stroke (HR 0.61) [1]. In the pre-specified subgroup of patients 65 and older, the direction of benefit was consistent, though the confidence intervals widened due to smaller subgroup size [1].

SELECT Trial and Older Adults Without Diabetes

The SELECT trial (N=17,604) tested semaglutide 2.4 mg in adults with obesity and established CVD but without diabetes. Published in the NEJM in 2023, SELECT showed a 20% reduction in MACE (HR 0.80, 95% CI 0.72 to 0.90) over a mean follow-up of 39.8 months [9]. The mean participant age was 61.3 years, with approximately 30% of participants older than 65. The cardiovascular benefit appeared consistent across the age subgroup, supporting a potential role for GLP-1 therapy in older adults with high CV risk even without diabetes [9].

Safety Concerns Specific to the Geriatric Population

Sarcopenia and Muscle Loss

Sarcopenia affects an estimated 10 to 27% of community-dwelling adults over 65 [6]. GLP-1-mediated weight loss is not fat-selective. Resistance exercise and adequate protein intake (at least 1.2 g/kg/day per many geriatric nutrition guidelines) may partially offset lean mass reduction, but no large randomized trial has specifically tested a protein-plus-exercise intervention alongside semaglutide in patients older than 70.

A practical clinical framework before initiating Ozempic in adults 65 and older:

1. Screen for sarcopenia: grip strength <27 kg (men) or <16 kg (women) per the EWGSOP2 criteria, or SARC-F score >4.
2. Assess nutritional status: Mini Nutritional Assessment (MNA) score; hold or defer if MNA indicates malnutrition (<17 points).
3. Review concurrent hypoglycemic agents: reduce sulfonylurea dose by 50% before starting semaglutide; consider insulin dose reduction of 10 to 20%.
4. Baseline renal function: obtain eGFR and electrolytes; repeat at 3 months if eGFR <45.
5. Fall risk assessment: Timed Up and Go test and orthostatic blood pressure check, given that hypoglycemia and dehydration both increase fall risk.
6. Set a reassessment point: weigh at 12 weeks; if weight loss exceeds 5% of body weight without intentional caloric restriction, reassess the risk-benefit profile for that patient.

Hypoglycemia Risk

Semaglutide as monotherapy carries a very low intrinsic risk of hypoglycemia because its insulin-releasing effect is glucose-dependent [3]. The risk rises sharply when combined with a sulfonylurea or insulin, both of which are common in older patients with long-standing type 2 diabetes. In SUSTAIN-7 (N=1,201), documented symptomatic hypoglycemia occurred in 7.1% of patients on semaglutide 1.0 mg plus sulfonylurea [10]. The ADA 2024 guidelines recommend reducing or stopping the sulfonylurea before adding a GLP-1 receptor agonist in patients at elevated hypoglycemia risk, a recommendation with particular weight in adults older than 65 who may have impaired hypoglycemia awareness [3].

Bone and Fall Risk

Rapid weight loss is associated with bone mineral density reduction. A secondary analysis of STEP-1 found a 0.5 to 1.2% reduction in hip bone mineral density over 68 weeks with semaglutide 2.4 mg [4]. Although the absolute change was small, older adults often have baseline osteopenia or osteoporosis. Prescribers should document DEXA scan status before initiating semaglutide for off-label weight loss in adults over 65, particularly postmenopausal women.

Gastroparesis and Delayed Gastric Emptying

Semaglutide delays gastric emptying, which can exacerbate subclinical gastroparesis. Older adults with long-standing diabetes have a higher baseline prevalence of gastroparesis, estimated at 30 to 50% in some series [2]. If a patient reports early satiety, bloating, or inconsistent postprandial glucose excursions before starting Ozempic, a gastric emptying study is reasonable before initiating therapy.

Drug Interactions Relevant to Older Adults

Oral Medications With Narrow Therapeutic Windows

Because semaglutide delays gastric emptying, it may alter the absorption rate (not total bioavailability) of oral medications. Drugs with narrow therapeutic indices warrant attention. Levothyroxine, which many older adults take, should be taken 30 to 60 minutes before the first meal, and thyroid-stimulating hormone (TSH) should be rechecked 6 to 8 weeks after semaglutide initiation [2]. Warfarin INR can become unpredictable if dietary intake changes significantly during the initial nausea period; more frequent INR monitoring is reasonable.

Diuretics and RAAS Agents

Volume depletion from GI side effects combined with continued thiazide or loop diuretic use raises the risk of acute kidney injury. A 72-year-old taking hydrochlorothiazide 25 mg daily who develops two weeks of semaglutide-induced nausea may lose enough volume to tip borderline eGFR of 42 into dialysis territory. Temporarily halving the diuretic dose during the first 8 weeks of semaglutide titration is a reasonable precaution in this scenario, discussed with the prescribing cardiologist or nephrologist.

Special Populations Within the Geriatric Group

Adults Over 80

No dedicated trial has enrolled patients primarily older than 80 in a GLP-1 receptor agonist study. Available data come from subgroups and case series. The SUSTAIN program enrolled patients up to age 93, but the number of patients older than 80 in any individual trial arm was likely in the low dozens [1]. Prescribing Ozempic to an octogenarian requires a frank goals-of-care conversation. If the primary goal is A1c reduction in a patient with a 5-year life expectancy, a target A1c of 7.5 to 8.5% per ADA geriatric guidelines may be adequate with less aggressive therapy [3].

Older Adults With Chronic Kidney Disease Stages 3b, 5

As noted, semaglutide requires no renal dose adjustment. Kidney outcomes data are also favorable: in FLOW (N=3,533, mean age 66.7 years, all patients had CKD and T2DM), semaglutide 1.0 mg weekly reduced the composite of kidney failure, 50% eGFR decline, and renal death by 24% versus placebo (HR 0.76, 95% CI 0.66 to 0.88) [11]. This trial provides direct evidence supporting semaglutide use in older adults with CKD, one of the most common comorbidities in this population.

Monitoring Protocol for Older Adults on Ozempic

Every patient 65 and older started on Ozempic should have:

• Baseline labs: fasting glucose, A1c, comprehensive metabolic panel, lipid panel, TSH, CBC
• Weight and BMI: documented at initiation and every 4 weeks for the first 3 months
• Functional assessments: SARC-F, Timed Up and Go, orthostatic vitals
• Medication reconciliation: sulfonylurea and insulin doses reviewed and adjusted before first injection
• Follow-up call at 2 weeks: specifically to screen for nausea, vomiting, reduced oral intake, and dizziness
• 3-month visit: A1c, eGFR, electrolytes, weight, reassessment of lean mass and functional status
• 12-month DEXA: if off-label use for weight loss in a patient with baseline osteopenia risk

The 2-week follow-up call is the single step most likely to prevent a hospitalization in this age group.

What Geriatric Specialists Say

The American Geriatrics Society's 2023 Beers Criteria does not list GLP-1 receptor agonists as potentially inappropriate medications for older adults, a meaningful absence given the list's comprehensiveness [12]. The criteria do flag sulfonylureas as high-risk due to prolonged hypoglycemia risk in older adults, which indirectly supports transitioning patients from sulfonylureas to GLP-1-based regimens when clinically feasible [12].

The Endocrine Society's 2023 clinical practice guideline on obesity states: "In older adults, the decision to treat obesity should weigh the benefits of weight loss against the risks of muscle and bone loss, and functional decline" [13]. That framing applies directly to off-label Ozempic use for weight management in patients 65 and older.